← prelander teardowns

Top 5 Astaxanthin Supplements of 2026 – Rovina

tryrovina.com (Rovina) · family top5 · open the live page ↗ · kept on the prelander swipe · found on the store (not yet seen behind an ad)
ArchitectureF4 — One first-person narrator, unnamed: an 'I' in the headline, the lead and the list intro, bylined as a team and replaced by 'our list' inside the cards. The auto tag F4 (ranking) stands. House framework 4 is a zero-narrator page; this one borrows a tester's voice for the first screen and drops it. Winner-first order: the seller's product is card one of five, on the seller's own domain, under a magazine-style masthead. Narratoran unnamed tester who says 'I', bylined as an editorial research team with a stock-style portrait (editor, 1) Big ideaAstaxanthin works and most bottles fail to deliver it; a short formulation test (dose, source, delivery) picks out the one that does. Hook devicefirst-person tester's verdict VillainCost-cutting brands (low doses, synthetic sources, dry capsules) run by marketers; one named direct-response rival is cast as a scam. What they call itNo coined name. Three formulation factors (the 12 mg clinical dose, a natural microalgae source, oil-based delivery) plus a four-to-six-week tissue-saturation clock that is later used against rivals' 30-day returns. Proof stack70+ peer-reviewed studies, none named · letter grades from A-plus to D-plus with no scoring method · third-party testing claimed, no certificate shown or linked · an unnamed pharmacist's recommendation · a claim that 50+ supplements were evaluated (five are shown) · an expose of one rival's marketing, with no evidence shown · a ranking system named only in the fine print OfferNo price table and no pack price. A cost of $0.33 a day, a 90-day money-back guarantee, online only. The last button offers a 90-day risk-free trial. Reader enters / leavessolution-aware → most-aware Product first named15% down the page · 3 buttons, the first at 34%

The two chiefs

House chief · 5/10

sponsored ranking advertorial on the seller's own store · first click from cold native traffic · adults comparing astaxanthin brands · solution-aware · a three-factor formulation test (dose, source, oil delivery) plus a four-to-six-week saturation clock

Lead: Problem-solution lead built on the reader's failed purchase. Grade B: fast and recognisable in five short paragraphs, but the headline's tested-it promise is never paid.
Offer: Thin on the page: a daily figure with no pack price, a 90-day guarantee, no bundle, no bonus, no reason for the price. The offer lives on the product page.
Close: Three stages (recap as ticks, motive, rule-of-thumb close) and one button that names the guarantee. No urgency apart from the sells-out line in the winner's card. Adequate.
Throughline: Vindication on the first screen, a long comparative middle with nothing felt in it, a jolt of indignation at card four, and a money fear to close. It sags in cards two, three and five.

Strongest

  • the order of agreement: rules first (entry 13), winner second, rivals as proof by contrast, rules back as ticks (entries 41-42)
  • the time-to-effect figure planted in the winner's card (entry 19) and spent in four later entries
  • the failed-bottle replay and the turn (entries 10-11)
  • concession before every markdown (entries 23, 27, 31, 36)

Weakest

  • proof: nothing on the page can be checked (no study named, no certificate, no method, no price)
  • counts and dates that contradict each other (entries 5, 12, 13, 40)
  • two fake drawbacks in the winner's card (entry 17)
  • a card that says avoid entirely ranked above a card whose fault is price (entries 34, 36)
  • soft buttons: two of three ask for a look (entries 22, 45)

Craft chief · REVISE

It reads like a spec sheet in a magazine's clothes: clear, scannable and flat, and it wakes up only when it attacks.

Strongest

  • entry 10: three fragments that replay the reader's own failed purchase; the best rhythm on the page
  • entry 11: the turn that clears the ingredient and blames the bottle, in two short sentences
  • entry 33: the one concrete picture on the page, placed after a list
  • entry 46: a rule of thumb delivered as a chant

Weakest

  • entries 23-30 and 36-39: three boilerplate cards whose verdicts repeat their own lists
  • entry 13: criteria miscounted and hidden behind closed toggles
  • entry 3 against entries 14 and 40: a test promised and never shown
  • entries 26, 30, 39: another site's fine print, three times

001 REVISE · entries 16, 20, 38: label-dash-gloss lines and parallel clauses drone; the only music is in entries 10 and 46. Cost: attention inside the winner's card. · 002 PASS·noted · the full movement is there (attention 3-4, belief 8-14, desire 15-20, action 40-47); two of three buttons ask only for a look, and the close never states a price or the next step. · 003 PASS·noted · plain throughout; the saturation term in entry 19 and the Latin species name in entry 16 go unexplained. · 004 REVISE · entries 23-30 and 36-39 are flat spots where a reader can stop with nothing lost; the criteria explanations are behind closed toggles (entry 13). Cost: the middle third of the page. · 005 REVISE · entry 3 promises a hands-on test; entries 14 and 40 show a label comparison and a different sample size. Cost: trust, for any reader who looks for the test. · 006 PASS·noted · real specifics at entries 29 (a percentage) and 33 (a yearly cost, an analogy); an abstract benefit list at entry 19. For the guard: the study count, the pharmacist, the daily price, the 50-plus sample. · 007 PASS·noted · the capture shows bold on the turn (entry 11), which is where a voice would stress; capitals mid-title in entry 13 and on one label in entry 32 shout. · 008 REVISE · entries 25 and 38 repeat their minus lists in sentence form. Cost: attention. · 009 N/A · a problem-solution lead; no story was selected and the 'I' never tells one. · 010 PASS·noted · entries 10-12 are spoken; entries 25 and 38 are written and hedged. · 011 PASS·noted · one picture only (entry 7), and it shows the ranking order before the argument; no product picture inside any card and no photographs of a test. · 012 REVISE · entries 26, 30, 39 ship another site's fine print; entry 1 is a theme default; entry 5 carries a stale date. Cost: trust if noticed. · 013 PASS · entries 8 and 10 name the reader's letdown in the reader's terms; from the first card on the page is about products. · 014 PASS·noted · vindication at entries 10-11, indignation at 32-33, little felt between them; no picture of life with the product working. · 015 REVISE · em dashes in most entries from 3 on; a throat-clearing frame at entry 11; contrast flips at entries 18 and 44. Tier 1 in copy someone else wrote: flagged, not rewritten. · 016 PASS·noted · the saturation term (entry 19) would fail a stranger; nothing on the first screen does. · 017 PASS·noted · curiosity and stakes are carried by entries 3-4 (money wasted); emotion is thin; the loop is closed by entries 13-15. · 018 PASS · colour: the ingredient-works, bottle-fails turn (entry 11); the saturation clock used against 30-day returns (entries 19, 25); the counterfeit-shop analogy (entry 33). Grey: cards two, three and five. · 019 N/A · no named person signs the page; the 'I' is anonymous (entry 5). · 020 REVISE · the lead and the close of this page recur on the store's 2026 review page, and one fine-print line appears three times here (entries 26, 30, 39). Cost: the second sighting reads as a template. · 021 N/A · not an email sequence. · 022 PASS·noted · the chant at entry 46 and the brackets at entry 41 are staccato that carries the positioning; a mechanical pass would flag them and should not. · 023 PASS·noted · the first screen names a ranking and the lineup shows the bag; what the buyer leaves with is never priced: no pack price anywhere. · 024 N/A · no verb hands the product a decision the buyer owns. · 025 PASS·noted · counts disagree: three and five factors (entries 12, 13); five and 50-plus products (entries 3, 14, 40); a 2025 date under a 2026 title (entry 5). Notes for the guard.

Take

  • Agree the rules before naming a brand: criteria first (entry 13), cards second, the same rules back as ticks at the end (entries 41-42). The reader's early yes becomes the verdict.
  • Plant a yardstick in the winner's card and spend it in the rival cards (entry 19 feeding 24, 28, 37). For us the yardstick is the routine and the verified lab test (b9, c3), because our guarantee is 30 days.
  • The failed-purchase replay in three beats (entry 10), followed at once by the turn that clears the ingredient and blames the bottle (entry 11).
  • Concede before marking down: every rival card opens with what it gets right (entries 23, 27, 36).
  • One number the reader can check inside a rival card (entry 29).
  • A lineup picture of all five packs above the lead (entry 7).
  • Winner first, with a button at the foot of its card a third of the way down (entries 15-22). CS-P1 already does this.
  • A rule-of-thumb close as a short chant of specifications (entry 46).
  • A recap section between the last rival and the close for the reader who skipped the cards (entries 40-43). CS-P1 lacks it.

Leave

  • The testing claim in the headline: no test is shown (entry 3).
  • FABRICATIONS: the anonymous team with a stock-style portrait (entry 5), letter grades with no method (entry 15), the unnamed pharmacist (entry 16), the ranking system named only in fine print (entries 26, 30, 39), the generic publication (entry 48), the 50-plus sample (entry 40).
  • The expose card (entries 31-35): fraud accusations against a named rival with no evidence shown. CL-13 and legal risk.
  • Unsupported rival defects: soy, 30-day returns, weaker testing (entries 24, 28, 37). Our own reading of two of these rivals' sites found different guarantee terms.
  • The 90-against-30-day argument: our guarantee is 30 days (CL-09).
  • Carrier-oil and absorption superiority (entries 13, 16): banned for us (b8).
  • Drawbacks that are compliments (entry 17).
  • Counts that disagree and a stale date (entries 5, 12, 13, 40).
  • Closed toggles over the criteria explanations (entry 13).
  • Buttons that ask only for a look, with no noun, price or guarantee (entries 22, 45).

Line by line · 48 entries

Every line is described in our words; the page's own text stays on the page (open it beside this table). Shaded rows carry the most pull.

#BeatWhat the line doesLever · readerWhy hereCraftOn our page
1
-0.0%
page-furniture
cta · 3 w
The store theme's accessibility link that jumps past the header to the main content.none
solution-aware
It is the first element in the document because the theme puts it there. Its presence shows the page is built inside the seller's own store theme and is not hosted by a separate publisher.Stock theme wording, untouched.page-furniture
CS-P1 is a static clone of the house top-5 chassis and needs nothing in this place.
2
0.2%
disclosure
cta · p · 5 w
A small advertiser-disclosure link in the masthead and an all-capitals label above the headline state that the page is paid advertising.candor
solution-aware
It stands before the headline because ad platforms check the first screen. Placed there, it is read before the reader has met a single claim to doubt, and it is never repeated near a button.Two labels, five words in all, set in grey. In the local capture the masthead beside them carries a magazine-style name and logo, so the page says advertisement and dresses as a publication in the same glance.keep-structure
CS-P1 carries its ad disclosure only in the footer; the byline's advertorial tag was removed on 2026-09-15. House law L-07 asks that the editorial chrome never contradict the disclosure strip. Whether a strip moves to the top is a call for David and the external claims reviewer. No Truth-Gate claim is involved.
3
1.1%
hook-headline
h1 · 11 w
A first-person tester says five well-known astaxanthin products were tried, and promises to say which things count when choosing one.earned-authoritycuriosity-gapspecificity
solution-aware
The reader arrives from an ad already sold on the ingredient, so the headline skips the case for astaxanthin and sells a filter for choosing a bottle. It needs the belief that bottles differ, and it sets up the factors and the list.Eleven plain words and one dash. The 'I' is the only voice on the page that claims hands-on work, and nothing below shows a trial: no method, no dates, no photographs, no results. The promise is paid with a reading of labels.keep-structure
CS-P1's H1 already promises a five-product ranking and, unlike this one, names the four organs (kidneys, brain, eyes, joints) as CL-04 asks. It speaks as an editor, and its honest verb is that the five were bought and their labels read. Keep ours. Do not borrow the testing claim, because no trial was run.
r10r6b3b4
4
2.3%
deck
p · 19 w
The deck says the writer studied the research and used several brands, and that what follows are the factors dividing astaxanthin that does something from a costly dud.loss-aversioncontrastopen-loop
solution-aware
It sits directly under the headline and above the byline, so the fear of a wasted purchase is in place before the reader asks who is speaking. It makes the lead's replay of a failed bottle feel like confirmation.One sentence of nineteen words. Its last two words are the only colour; the opening clause about studying the science is vague and could sit on any supplement page.keep-structure
CS-P1's subhead does this job with a count (five softgels, three tests, one winner) and its intro asks whether the bottle in the cabinet does anything. It has the move. Our evidence that bottles differ is c1: about 64% of unverified astaxanthin products fail third-party potency testing.
c1
5
3.5%
authority-stamp
2× p · 13 w
The byline credits an unnamed editorial research team. The date line shows an update in June 2025 and a reading time of four minutes.borrowed-authorityease
solution-aware
After the promise the reader asks who is talking. The answer comes as a format, not as a person, and the short reading time lowers the cost of continuing just as the body begins.FABRICATION: the headline says 'I', the byline says a team, and no person, credential or outlet is given. In the capture a stock-style portrait of a smiling woman sits beside the team credit. The date is a year older than the 2026 in the page title.rewrite-claim
CS-P1 already fills this slot and goes further: a named editor with a generated portrait, sixteen years of experience, a nine-minute read and a press strip of four magazine names. CL-14 forbids an invented authority figure, so the persona and the press names need David's confirmation or a plain editorial credit. This competitor attacks a rival for an unverifiable endorser in entry 32; the same attack could be turned on any invented byline.
6
4.2%
page-furniture
3× cta · 5 w
Three jump tabs name the page's parts: what the ingredient does, the dose, and the list of five.ease
solution-aware
They sit between the byline and the first picture, where a scanner decides whether to read or skip. In the capture the middle tab is the highlighted one, which pushes the dose as the first thing to check.Five words across three labels. The first tab promises a benefits section that the body never gives a heading to.page-furniture
CS-P1 has no jump tabs; its sticky bar and sidebar do the shortcut work. Not needed.
7
4.7%
image
img
A wide banner with no alt text. In the local capture it lines up the five ranked packs on a pale background, the seller's bag first on the left, in the same order as the ranking.identificationanchoring
solution-aware
It stands above the lead, so the reader knows five real brands are coming before any argument starts. Seeing a familiar bottle makes the coming criticism of it personal.The picture gives the result away: left to right is first to fifth. Real trade dress does the credibility work that the missing test photographs cannot do.keep-structure
CS-P1's hero is our own bag alone, captioned as the top pick, and each rival still appears only inside its card. It lacks one picture of all five together. A lineup built from the rival stills already on CS-P1 would do this job; alt text is customer copy.
8
6.2%
failed-solutions
h3 · 8 w
A section heading states that the usual experience with astaxanthin is to notice nothing.mirroringcuriosity-gapconsensus
solution-aware
These are the first words of the body. The deck said duds exist; the heading now says most buyers got one, which makes the reader's own flat result normal and blameless before any product is named.Eight words, no product, no promise. The claim about most buyers is unsupported, and the heading works anyway because it describes the reader.keep-structure
CS-P1 opens on the multivitamin that never gets to the cell (p3, r3, r5) and has no line for the reader who tried astaxanthin and felt nothing. For our reader in their 60s and 70s that is right: p7 says most of the market has never heard of astaxanthin. A retargeting variant could open on the failed bottle.
p3r3r5p7
9
6.8%
proof-study
p · 28 w
The first paragraph grants the ingredient its reputation: a very strong natural antioxidant with more than 70 peer-reviewed studies in five areas, from skin and eyes to joints, energy and recovery.borrowed-authorityconsensuscommitment
solution-aware
It is placed before the disappointment so the reader first says yes to the science. If the failed bottle came first, the reader could decide the ingredient is hype and leave.Two sentences and a list of five benefit areas. The study count comes without a single named study, and the five areas are broad enough for any reader to find one.swap-proof
CS-P1's intro carries the reputation in one line (about 6,000 times vitamin C, m3) and names four organs. It does not state a study count. Ours is r14 (60+ clinical studies), and r15 lets us call it nature's most powerful antioxidant.
r14r15m3
10
7.9%
failed-solutions
p · 15 w
Three short beats replay the reader's own history: bought it, took it for months, felt little.mirroringidentificationloss-aversion
solution-aware
It follows the praise of the science so the gap between promise and result is felt at full width. It has to come before the explanation, because an explanation is wanted only once the letdown is admitted.The best rhythm on the page: three fragments, the last trailing off on an ellipsis. Second person, no adjectives, fifteen words.keep-structure
CS-P1 has no replay of a failed purchase. Our equivalent for the senior reader is the cabinet of vitamins taken for years with nothing to show (r3, r23), which CS-P1's intro states as a fact and does not act out. Written as the reader's own history in short beats it would land harder. Never the collagen-plateau story (p1).
r3r23
11
8.4%
villain-reveal
p · 13 w
The turn: the ingredient is cleared, and the blame moves to products that fail to deliver it.vindicationcontrastcommon-enemy
solution-aware
It comes straight after the letdown, while the reader is asking why. It keeps the wish for astaxanthin alive and makes brand choice the only open question, which is the question a ranking answers.It opens on a throat-clearing frame, then gives two short sentences; the capture shows them in bold. The second sentence is soft: it says some products underdeliver and does not say how.rewrite-claim
CS-P1 has the fact (c1, in the method box) without the turn. Our culprit is the unverified bottle: about 64% fail third-party potency tests (c1), and a tested badge is a claim while verified lab results are proof (c3; David's 2026-09-15 wording for CS-P1 is lab tested, with no QR-code line). Their delivery argument rests on carrier oil, which is banned for us (b8).
c1c3
12
9.0%
turning-point
p · 24 w
The narrator reports a finding from the research: three factors decide whether a supplement does its job or simply leaves the body unused.earned-authorityspecificityopen-loop
solution-aware
It bridges the culprit to the criteria. The reader now believes bottles differ and wants to know how to tell; the number three makes the answer feel learnable before the list begins.One sentence in the first person, with a dash before the consequence. The research is referred to as vaguely as in the deck. The count of three is contradicted by the very next heading.keep-structure
CS-P1 has this: its subhead and intro promise three tests. Its method box then lists five things, the same slip in counting this page makes between entries 12 and 13. Settle on one number.
13
10.1%
ranking-criteria
h2 · 3× h3 · h4 · 2× cta · 29 w
A heading announces five critical factors. Only three follow, as numbered toggle titles: the 12 mg dose as the clinical standard, a natural microalgae source for bioavailability, and oil-based delivery over dry powder.reason-whyspecificitycommitment
solution-aware
Criteria come before the cards so the reader agrees to the rules while no brand is at stake. Each rule is one the seller's product meets, so agreeing here is agreeing to the winner in advance.The heading says five, the lead said three, three are shown. The explanations sit behind closed toggles (the capture shows plus signs), so a reader who does not tap gets titles only. One title switches to capitals halfway through.rewrite-claim
CS-P1 has the method box, open and explained, which is better than closed toggles. Ours rest on b7 (12 mg against the 4 to 6 mg brands), c4 (natural microalgae, the form in the positive human studies), c1 and c3 (lab testing) and b9 (one softgel a day). Their third factor, oil against powder, is a carrier argument and stays out (b8).
b7c4c1c3b9
14
12.9%
ranking-criteria
h2 · p · 24 w
The list's title, then one sentence of method: the narrator examined five popular products and scored them on four things, the three rules plus value.earned-authorityspecificity
solution-aware
It is the last line before the first card. A fourth yardstick, value, is added only now, after the three formulation rules were agreed; price enters as a tiebreaker the seller expects to win.The verb has weakened from the headline's testing to looking. Eighteen flat words. Nothing on how the five were chosen or how a grade is worked out.keep-structure
CS-P1 has this and is more honest about it: the five are the ones people over 50 buy, the labels were read, and the price is worked out per day from each brand's own site. It also says which test every rival passes and that it therefore did not decide the order (L-04).
15
14.7%
ranked-entry
h2 · h3 · 2× p · 9 w
Card one: the seller's own 12 mg product, credited to its maker, under the top letter grade.anchoringcontrast
product-aware
The winner leads the list. A scanner who reads one card reads this one, and every later card is then read against it. The cost is that the result is known at once, on the seller's own domain.FABRICATION: a letter grade with no scoring method anywhere on the page. Four short lines and no claim yet.keep-structure
CS-P1 also puts our product first, with three scored bars in place of a letter, and gives itself 7.5 on cost per day, which a letter cannot show. Keep the bars. Two things to fix on CS-P1: the rival scores do not fall in rank order (the second-ranked card has the lowest numbers), and one rival's body names a rank it does not hold.
b7c3
16
17.0%
ranked-entry
h1 · 9× p · 85 w
Nine plus points, each a bold label with a gloss: dose, source, coconut-oil softgel, third-party testing, clean label, traceable sourcing, the 90-day guarantee, a pharmacist's recommendation, and the lowest daily cost at 33 cents.specificityreason-whysocial-proofrisk-reversalanchoring
product-aware
The longest list on the page sits in the first card, so every rival's shorter list looks thin beside it. The first three lines repeat the three agreed rules in order, so the card opens by passing the test.Label, dash, gloss, nine times: steady and scannable, and by the sixth line it drones. FABRICATION: the pharmacist is unnamed, and batch testing is claimed with no certificate shown. The daily price appears with no pack price to check it against.rewrite-claim
CS-P1's winner card has five plus points of one line each, and that restraint reads better. Ours: the full 12 mg in one softgel (b7, b9), every batch third-party lab tested (c3), natural microalgae from closed bioreactors with no heavy metals (c4, c5), the 30-Day Money-Back Guarantee, free shipping. We cannot claim the lowest cost per day: our best tier is 60 cents. No carrier-oil line (b8).
b7b9c3c4c5
17
22.5%
ranked-entry
h1 · 2× p · 11 w
Two minus points for the winner: it is sold only online, and it often runs out because so many people order it.candorscarcitysocial-proof
product-aware
A card with no drawbacks would read as an advert, so two are supplied right after the nine plus points. The second plants the idea of stock running out, which the runner-up's card relies on in entry 25.Ten words in total. Neither is a real cost to the buyer, and the second is a boast. A reader who notices loses trust in every other minus point on the page.keep-structure
CS-P1 has the better version, under a heading that replaces the word cons: it is a supplement and not a treatment, it is sold only on the official site (r29), and the multi-bag prices are launch pricing. The first of those is a real limit. Keep ours, and add no sold-out line unless stock is truly short.
r29
18
24.1%
ranked-entry
h3 · 2× p · 45 w
The verdict opens: this is the only product on the list to meet every requirement, and its 12 mg natural, oil-based softgel is said to match what the studies used and not a cheaper cut.exclusivityborrowed-authoritycontrast
product-aware
After the lists the reader needs a conclusion before the longer argument. The claim to be the only one is made here, ahead of the rival cards that are supposed to prove it.The voice has moved from 'I' to 'our list'. Two sentences; the second ends on a two-adjective jab at cheaper products, the first sign of heat in the card.rewrite-claim
CS-P1 has this as the callout that explains why our product took the top spot: the only one passing all three tests at once. It rests on b7, c3 and the daily price. c4 lets us say that the natural, microalgae-derived form is the one used in the positive human studies.
b7c3c4
19
26.2%
ranked-entry
2× p · 60 w
Two further paragraphs: a claim of full transparency (test certificates, traceable sourcing, clean label), then the assertion that it works, with tissue saturation at four to six weeks and reported gains in energy, recovery, joints, skin and cell function.reason-whyspecificityfuture-pacingnew-mechanism
product-aware
The four-to-six-week figure has to appear in the winner's card, before any rival, because every later attack on a 30-day return (entries 24, 25, 28, 37) depends on the reader already holding it.The strongest structural sentence on the page is dressed as a passing fact. The saturation term is unexplained jargon. The benefit list is five abstractions in a row. The certificates are mentioned and never shown or linked.rewrite-claim
CS-P1 has a week-by-week timeline, placed after the cards, where it cannot serve as a yardstick. Ours: energy in weeks 1 to 2 (r7), eye strain relief in 14 to 28 days (b6), gut in weeks 4 to 8 (r8), kidney labs re-drawn at 8 to 12 weeks (r10). Their use of the figure to condemn 30-day returns cuts against our 30-Day Money-Back Guarantee, so our yardsticks are the routine and the verified lab test (b9, c3).
r7b6r8r10b9c3
20
28.9%
ranked-entry
h3 · 3× p · 92 w
The card's summary casts rivals as corner-cutters (small doses, synthetic raw material, dry capsules) and this product as treating oxidative stress at its origin with the three rules met, at 33 cents a day, filler-free, with 90 days to judge.common-enemycontrastreason-whyrisk-reversal
product-aware
A scanner reads the top and the bottom of a card. This summary repeats the three rules, adds the price and ends on the guarantee, so the button below it follows a risk-free thought.Three paragraphs; the middle one is four parallel clauses with a bracket after each, and reads like a spec sheet spoken aloud. The guarantee is given a reason (the time needed to judge), which is the best sentence here. The phrase about root causes is large for an antioxidant.rewrite-claim
CS-P1's winner body does this in two paragraphs. Ours: the 4 to 6 mg brands against the full 12 mg (b7), synthetic against natural (r16, c4), and the guarantee under its one name, the 30-Day Money-Back Guarantee. Our daily price is higher than theirs, so the summary closes on the verified lab results (c3) and not on price.
b7r16c4c3
21
32.9%
disclosure
fine · 25 w
Fine print under the card: results reflect users' own experience, may not be typical, and the product site has more.none
product-aware
It comes after the claims and before the button, in the smallest type, where it protects the seller without slowing the reader.Stock wording, 25 words. It speaks of users' experiences although the card quoted none.page-furniture
CS-P1 carries its supplement disclaimer and ad disclosure once, in the footer. No fine print is needed under each card.
22
33.9%
cta
h2 · 5 w
The first link to the product: an invitation to find out more about the brand, with an arrow.commitmentease
product-aware
It closes the winner's card at 34% of the page. Before it there was nothing to click; after it the reader is inside the rival cards. The wording asks for a look and not a purchase, which suits a reader with four cards still unread.Four words and an arrow, styled as a heading. No price, no guarantee, no noun for what waits on the other side.swap-offer
CS-P1 has a full block after the winner card: the noun, the per-bag price from the 5-bag tier, free shipping and the 30-Day Money-Back Guarantee. Ours is stronger. CL-16 asks for one button vocabulary per funnel; CS-P1 currently uses three labels.
23
34.9%
ranked-entry
2× h2 · 7× p · h1 · 37 w
Card two: Sports Research, grade B-plus. Five plus points grant it the 12 mg dose, a natural source, a coconut-oil softgel, third-party testing and non-GMO sourcing.candorcontrast
product-aware
Second place has to be a credible rival that passes the agreed test. Having granted that, the page must mark it down on grounds the criteria section never named.The glosses shrink to two or three words each, against full phrases in the winner's card. The thinness is itself the markdown.keep-structure
CS-P1 does this for every rival and with checked facts: each rival's format, count, serving and price were read on its own product page on 2026-09-14 (CL-13, L-04). Keep ours.
24
39.1%
ranked-entry
h1 · 4× p · 38 w
Four minus points: it is said to contain soy, to offer no batch-level verification, to allow only 30 days for returns, and to test less strictly.contrastloss-aversion
product-aware
The rival passed the three rules, so new yardsticks appear only now: allergen, batch proof, return window. The return window counts as a flaw only because entry 19 set the four-to-six-week clock.UNSUPPORTED: no label, link or test is shown for any of the four. The last point compares testing standards without naming either standard. Our own reading of this rival's site on 2026-09-14 found a guarantee badge with no stated term.rewrite-claim
CS-P1 marks this rival down on one checkable point: a tested badge with no batch report to open (our answer is c3), plus a guarantee that states no term. It also credits the rival as the cheapest per day. That is the fair version (CL-13). Never claim an ingredient or a test result we did not read on the rival's own page.
c3
25
41.9%
ranked-entry
2× h3 · 3× p · 92 w
The verdict grants the basics, says soy and missing batch proof cost it first place, and argues a 30-day return cannot test a product needing four to six weeks. The summary: a fallback if the winner is sold out.contrastreason-whyscarcitycandor
product-aware
Recommending the rival only when the winner is unavailable does two things at this point: it sounds generous, and it reminds the reader of the stock warning from entry 17.Three paragraphs that repeat the minus points in sentence form. The one fresh idea is the fallback line. The register turns written and hedged where the lead was spoken.rewrite-claim
CS-P1 gives each rival a one-line verdict tag and a two-paragraph body, which is tighter. We cannot use the return-window argument, because ours is 30 days. Our gap against this rival is verified batch results (c3).
c3
26
45.9%
disclosure
fine · 22 w
Fine print credits the results to a named ranking system and says they may not reflect typical outcomes.borrowed-authority
product-aware
It sits under the rival's card, where a grade has just been given, so the grade seems to come from a system.FABRICATION or leftover: the Smarter Reviews system it names is described nowhere on the page. The name belongs to a known review-site template, which suggests the page was cloned and the line never edited.drop
CS-P1 shows its three tests and the numbers on every card, so it needs no named system. Do not invent one.
27
47.3%
ranked-entry
2× h2 · h3 · 5× p · h1 · 35 w
Card three: NOW Foods, grade C-plus. Four plus points: natural source, an oil softgel with MCT oil, a lower price, and wide availability in shops.candorcontrast
product-aware
Third place is where a rival first fails one of the three agreed rules. The ranking needed two passes before a fail, so the rules look as if they discriminate.Short glosses again. Price and shop availability are credited as virtues here and nowhere claimed for the winner.keep-structure
CS-P1 has no rival under 12 mg: all five are 12 mg products (CL-13, same species). The underdosed brand appears in our copy only as a class, the 4 to 6 mg brands (b7), and not as a ranked card.
b7
28
51.2%
ranked-entry
h1 · 5× p · 41 w
Five minus points: a 10 mg dose, generic ingredients, ordinary quality control, a 30-day return, and soy with other fillers.contrastspecificityloss-aversion
product-aware
The dose shortfall leads the list because it is the only point tied to the agreed criteria. The rest repeat the secondary yardsticks introduced in the card before.Only the first point can be checked from a label (the lineup picture shows 10 mg on the bottle). The two points about ingredients and quality control are judgments with nothing behind them.rewrite-claim
Our dose argument is b7: 12 mg against the 4 to 6 mg brands, stated as a spec and in the method box. CS-P1 already has it and turns it into a point about routine: the full 12 mg in one softgel, where one rival needs four a day (b9).
b7b9
29
54.2%
ranked-entry
2× h3 · 3× p · 83 w
The verdict calls it a budget choice, adequate for casual use and disqualified for anyone wanting the full dose. The summary works the shortfall out as 17 percent under 12 mg and urges paying for an effective dose.specificitycontrastloss-aversionidentification
product-aware
The page splits readers into casual and serious here, halfway down, so that staying with a cheaper bottle becomes a statement about the reader. It prepares the closing line about wasted money in entry 46.The percentage is the sharpest detail in any rival card: arithmetic the reader can check. The investing verb is used twice in one sentence.rewrite-claim
The arithmetic move transfers: state a gap as a number the reader can verify. Ours on CS-P1 is four softgels a day against one (b9) and a bag that lasts 15 days, both read from the rival's page. Never the human-capital framing (p8).
b9b7
30
58.1%
disclosure
fine · 22 w
The same fine print as under card two, naming the ranking system again.borrowed-authority
product-aware
Same slot as in entry 26: under the grade, lending it a source.Word for word the line from entry 26. A leftover from the template.drop
Nothing stands here on CS-P1.
31
59.4%
ranked-entry
h2 · h3 · 4× p · h1 · 32 w
Card four: Clarity MD. The grade label is there with no letter captured. Three plus points grant the 12 mg dose and the oil softgel, and word the natural source as something the brand asserts.candorcontrastopen-loop
product-aware
The page concedes the softgel first. That makes what comes next read as fairness, and it answers in advance the reader who thinks the rival's formula looks the same as the winner's.The third plus point is hedged with two distancing words, the only hedged praise on the page. It signals the turn before the minus list starts.drop
CS-P1 ranks only comparable products and says nothing about a rival's conduct (CL-13). No card of this kind.
32
63.3%
ranked-entry
h1 · 7× p · 118 w
Seven accusations: an unverifiable doctor endorser, disease-treatment marketing with no product trials, illegal disease promises (dialysis, macular degeneration, fatty liver), invented reviews, evergreen countdown timers, testing claimed with no certificate or lab name, and a false country of origin.common-enemyspecificitycontrastpattern-interrupt
product-aware
It is fourth, past the halfway mark, where a list usually sags. Three polite cards have set a calm tone, so the change of register jolts the reader awake. It comes after the winner so the accusations define the winner by contrast.The most specific writing on the page: a named persona, quoted promises, a list of tactics. One label is in capitals and one line has a typing error. UNSUPPORTED on this page: no screenshot, link or record backs any of the seven. The same store publishes kidney-angle advertorials (five are in this research set), so the stance is tactical.drop
Not transferable. CL-13 allows only fair, verified comparisons between comparable products, and an accusation of fraud is a legal risk. Our category-level substitute is c1 (about 64% of unverified products fail potency tests) and c2 (the Amazon leader stopped publishing its certificates), stated without naming a culprit. WARNING for our side: the disease promises listed here belong to the family our gate holds as r10 and r11, and CS-P1's final block ties the product to the reader's next labs. The external claims reviewer should see this card.
c1c2
33
69.7%
ranked-entry
h3 · p · 90 w
A long verdict: a genuine ingredient proves nothing about the seller. The softgel may be fine; the operation is called a scam that takes over $2,000 a year by subscription. An analogy: a genuine watch from a fake shop.common-enemyloss-aversionspecificitycontrast
product-aware
After seven bullet accusations the reader needs a single idea. The analogy supplies it, and the yearly cost converts indignation into a money fear at the moment the reader might think the rival sells the same softgel.The longest paragraph on the page and the only one with an image in it. The analogy is fresh and exact. The sentence before it stacks four accusations and a dash and runs long. The yearly figure comes with no arithmetic.drop
Not transferable (CL-13). The craft lesson transfers: one concrete picture after a list. CS-P1's rival bodies have plain facts and no picture; the nearest is the tested badge with no report to open.
34
72.9%
ranked-entry
h3 · p · 64 w
The summary tells the reader to avoid the brand completely and to buy from a company with reputable retail, real test results and no disease claims, with a special warning for anyone who has the conditions its ads mention.common-enemycontrastloss-aversion
product-aware
The order to avoid comes last in the card, after the evidence, so it reads as a conclusion. The description of a trustworthy brand doubles as a checklist the reader will apply to the winner in the recap at entry 40.61 words: a four-word order, then two long sentences, the second with a semicolon and a dash. The advice to buy through reputable retailers contradicts the winner's own card (sold only online), and the next card faults a rival for being sold at retail.drop
Not transferable (CL-13). What we can say in our own voice is already on CS-P1's list of things worth knowing: a supplement and not a treatment, keep your doctor and your labs.
35
75.5%
disclosure
fine · 27 w
Fine print unique to this card: the verdict rests on a review of the rival's marketing, sales page and checkout flow, and makes no statement about what is inside its softgel.candor
product-aware
It stands directly under the harshest card, where the risk of a defamation complaint is highest. It is the one fine-print line on the page that was written for this page.27 words, precise, lawyerly. It quietly concedes the softgel may be fine, which the card's own opening already granted.drop
No such card on our page, so no such line.
36
77.0%
ranked-entry
2× h2 · h3 · 4× p · h1 · 28 w
Card five: BioAstin by Nutrex Hawaii, grade D-plus. Three plus points: grown in Hawaii, an oil softgel, a well-known name.contrastpattern-interrupt
product-aware
The oldest name is placed at the bottom, under the brand the page called a scam. A reader who came in trusting the heritage brand meets it with the worst grade, which unsettles the default choice.The order breaks the page's own logic: the card above says avoid entirely, yet it outranks this one, whose worst fault is price. The plus points are three-word glosses.keep-structure
CS-P1 ranks the same brand third and treats it fairly: the full 12 mg in one gelcap, among the cheapest per day, no batch report on the product page. L-04 says the incumbent the buyer already owns stays as the foil. Keep ours.
37
80.8%
ranked-entry
h1 · 5× p · 38 w
Five minus points: a 30-day return, a 25-day supply that means frequent reorders, poor value, the chance of uneven storage and freshness in retail channels, and a steep daily cost.contrastloss-aversion
product-aware
It is the last card, so the markdowns are the commercial ones the recap is about to praise in the winner: guarantee length and cost per day. The reader goes from this list straight into the winner's checklist.Two of the five say the same thing about price. The formatting differs from the other cards (no bold labels, a bracketed aside), a sign it was written at another time. Retail availability was a plus in card three and is a minus here. UNSUPPORTED: our reading of this rival's site on 2026-09-14 found a 45-day guarantee.rewrite-claim
CS-P1's markdowns on this rival are the checkable ones: no third-party test on the product page, a 45-day guarantee that may ask for the product back, out of stock when checked. Our answer is c3.
c3
38
83.8%
ranked-entry
2× h3 · 2× p · 70 w
A flat product description, then a summary that grants dose and delivery and faults daily cost, bottle size and thin testing disclosure, against rivals said to give more for the money, longer refund windows and a more answerable seller.contrastcandor
product-aware
The mildest verdict is saved for last so the reader leaves the list on a shrug. The closing comparison names the three things the recap leads with: value, guarantee, accountability.The verdict is a label read aloud, with no judgment in it. The summary has 42 words in two sentences; the second holds three faults and three comparatives, six items at once.keep-structure
The move is to end the rivals on the commercial points that the closing section then claims for the winner. CS-P1 ends its rivals on a catalogue brand marked down on price and proof, then goes to the timeline. It has the structure.
39
87.5%
disclosure
fine · 22 w
The ranking-system fine print, a third time.borrowed-authority
product-aware
Same slot as entries 26 and 30.Identical to entries 26 and 30. Three sightings of one leftover line.drop
Nothing stands here on CS-P1.
40
88.7%
differentiation
h2 · p · 19 w
A heading declares a clear winner by name. One sentence says more than 50 supplements were evaluated and a single brand met every factor.exclusivityspecificityloop-closed
product-aware
It comes right after the fifth card, when the reader who read every card is ready for a conclusion and the reader who skipped needs one. The sample grows from five to over 50 at the moment of the verdict.INCONSISTENT: the headline tested five, the list examined five, and the recap evaluated more than 50. The heading names the winner, so the suspense the next lines try to build is already spent.keep-structure
CS-P1 has no recap between the last rival and the timeline; its final heading asks whether the reader is ready for the one that passed all three tests. A short recap would serve the reader who skipped the cards. Keep the count honest: five products, labels read.
41
90.0%
differentiation
4× p · 20 w
Four ticks restate the formulation rules, each with a bracketed comment: the 12 mg dose, the microalgae source, the oil softgel, and third-party testing.commitmentspecificityreason-why
product-aware
The rules the reader agreed to at the start return as ticks, all passed. Because the reader accepted them before any brand was named, the ticks feel like the reader's own verdict.Two or three words each, then a bracket. The brackets carry the attitude; one says the dose is not up for negotiation.rewrite-claim
CS-P1's proof bar (three short claims under the timeline) is the nearest thing; it is not framed as the tests coming back. Ours: the full 12 mg in one softgel (b7, b9), natural microalgae (c4), every batch third-party lab tested (c3). No tick for a delivery oil (b8).
b7b9c4c3
42
91.2%
differentiation
3× p · 19 w
Three further ticks cover the commercial side: a clean label free of fillers and soy, the 90-day guarantee, and the 33-cent daily cost.risk-reversalanchoringcontrast
product-aware
These come after the formulation ticks because they are the tiebreakers: three rivals passed the formulation rules, and none was granted all three of these.The clean-label bracket ends on a slang insult for synthetic additives, a register the rest of the page does not use. The price tick is the third repeat of the same figure.swap-offer
Ours: the 30-Day Money-Back Guarantee with the bag kept, free shipping, and from $17.99 a bag on the 5-bag tier (60 cents a day). r18 covers the badges (cGMP, made in USA, gluten-free, no stimulants). CS-P1 has these in the winner card and the proof bar.
r18x4
43
92.3%
product-reveal
p · 4 w
A four-word line names the brand as the one that met everything.loop-closed
product-aware
It is held until after the seven ticks so the name arrives as a conclusion. The heading at entry 40 had already given it away.Four words in a paragraph of their own. Good rhythm after a list, and wasted by the heading that named the winner nine lines earlier.keep-structure
If CS-P1 adds a recap, its closing line names The Cell Shield, the full noun (CL-02). CS-P1's final heading already points at the product without the name.
44
92.8%
differentiation
h2 · 3× p · 47 w
A short section claims that marketers chasing margin run most of the category, while people who understand cell biology run this brand and therefore made one that meets every rule.common-enemycontrastreason-why
product-aware
After the checklist a reader may ask why one brand would do all this when others do not. The answer offered is character. It comes late because it would sound like advertising before the evidence.UNSUPPORTED: no founder, scientist or team is named. Three sentences; the last borrows the cadence of a famous speech about choosing hard things. The first line is missing its full stop.rewrite-claim
CS-P1 has no section on who makes the product. Our true version is practice and not character: every batch third-party lab tested (c3), grown in closed bioreactors (c5). r19 allows a longevity doctor's recommendation with a quote once David confirms the doctor (CL-14).
c3c5r19
45
95.3%
cta
h2 · 5 w
The learn-more link again, in the same four words.commitment
most-aware
It stands at 95%, after the motive section. The wording is still the soft one from the first card, although the reader has now read the whole case.Identical to the first link. No escalation between a button at 34% and one at 95%.swap-offer
CS-P1's closing block has a heading, a two-sentence reason and a button with the guarantee. Ours is stronger.
46
95.9%
close
h1 · 3× p · 30 w
The close gives a rule of thumb: anyone taking astaxanthin should take the effective dose. A four-item chant of specifications follows, and a last line dismisses anything short of it as money thrown away.loss-aversionspecificitycommitment
most-aware
These are the final words before the last button. They return to the money fear from the deck, so the page ends where it began, now with the reader holding the answer.The best cadence after entry 10: a conditional sentence, four fragments, a verdict. The chant lists four items where the lead promised three. It sells the specification and not the brand.rewrite-claim
CS-P1's close says the difference is the full 12 mg in one softgel, lab tested and shipped free, and that it shows on the next labs. The chant form would sharpen it: 12 mg, one softgel, natural microalgae, every batch lab tested (b7, b9, c4, c3). The next-labs promise should go to the claims reviewer (r10, r11).
b7b9c4c3
47
97.9%
cta
h2 · 7 w
The last button asks the reader to try the brand for 90 days without risk.risk-reversalease
most-aware
Only the final button names the guarantee. The two before it asked for a look; this one asks for a trial, after the close has made not acting feel like waste.Six words and an arrow, with the first verb on any button that implies buying. Styled as a heading.swap-offer
CS-P1's buttons carry the noun and the 30-Day Money-Back Guarantee (CL-09). Check before traffic: the buttons land on the PDP's Try Before You Buy box (ob=c), which BRAND.md describes with a monthly lane and $6.99 shipping, while the line under the button says one-time purchase and free shipping.
48
99.5%
page-furniture
fine · 8 w
A copyright line in the name of a generic health-and-fitness publication.none
most-aware
Footer. It matches the masthead seen in the capture, and neither names a company, an address or an editor.FABRICATION: the publication exists only as a logo and this line, on the seller's own store domain.page-furniture
CS-P1's footer carries the house chassis's publication identity (a media company name, a founding year, a trademark line) beside the ad disclosure. L-07 asks that the chrome never contradict the disclosure strip.